HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) but lowers the price target from $35 to $19.

February 20, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Nurix Therapeutics but lowers the price target from $35 to $19.
The reduction in the price target from $35 to $19 by a reputable analyst firm like HC Wainwright & Co. could lead to a negative short-term impact on Nurix Therapeutics' stock price. This adjustment reflects a significant change in the expected future performance of the company, potentially influencing investor sentiment and stock valuation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100